Russell Frank Company’s Coherus Oncology CHRS Stock Holding History

Russell Frank Company’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$179K	Sell	8,448 -46,833	-85%	-$767K	﹤0.01%	2696
2015 Q4	$1.29M	Sell	55,281 -176,581	-76%	-$4.54M	﹤0.01%	2084
2015 Q3	$4.65M	Sell	231,862 -111,542	-32%	-$3.39M	0.01%	1318
2015 Q2	$9.93M	Buy	343,404 +266,584	+347%	+$6.74M	0.02%	991
2015 Q1	$2.35M	Buy	+76,820	New	+$1.99M	﹤0.01%	1683

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's CHRS Position: Q1 2016 in Review

Russell Frank Company reduced its Coherus Oncology (CHRS) stake by 85% in Q1 2016, selling an estimated $767K and leaving 8,448 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #2696.

Russell Frank Company first reported a position in CHRS in Q1 2015 and has held it in 5 quarters since. The position peaked at $9.93M in Q2 2015. 75 funds tracked by Wall St. Rank hold CHRS as of Q1 2016.

Russell Frank Company held 8,448 shares of Coherus Oncology worth $179K as of Q1 2016.
Russell Frank Company sold 46,833 Coherus Oncology shares in Q1 2016, an estimated $767K.
Coherus Oncology made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2696 holding.
Russell Frank Company first reported a position in Coherus Oncology in Q1 2015 and has held it in 5 quarters since.
Russell Frank Company's Coherus Oncology position peaked at $9.93M in Q2 2015.
75 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.